These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35144206)

  • 1. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Li JL; Hsieh TL; Ou MC; Lin FC; Tsai SC
    Oral Oncol; 2022 Mar; 126():105729. PubMed ID: 35144206
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    Head Neck; 2022 May; 44(5):1237-1245. PubMed ID: 35146824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
    Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.
    Gatfield ER; Tadross J; Ince W
    Future Oncol; 2024; 20(23):1695-1711. PubMed ID: 38889284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
    Issa M; Klamer BG; Mladkova N; Laliotis GI; Karivedu V; Bhateja P; Byington C; Dibs K; Pan X; Chakravarti A; Grecula J; Jhawar SR; Mitchell D; Baliga S; Old M; Carrau RL; Rocco JW; Blakaj DM; Bonomi M
    BMC Cancer; 2022 Jul; 22(1):767. PubMed ID: 35836204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Nishimura A; Yokota T; Hamauchi S; Onozawa Y; Shirasu H; Kawabata T; Ogawa H; Onoe T; Iida Y; Mukaigawa T; Yasui H
    Int J Clin Oncol; 2021 Oct; 26(10):1822-1830. PubMed ID: 34152533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Haridevamuthu B
    Oral Oncol; 2024 Sep; 156():106913. PubMed ID: 38955109
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
    Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
    Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
    Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
    Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
    Tanoue K; Tamura S; Kusaba H; Shinohara Y; Ito M; Tsuchihashi K; Shirakawa T; Otsuka T; Ohmura H; Isobe T; Ariyama H; Koreishi S; Matsushita Y; Shimokawa H; Tanaka R; Mitsugi K; Akashi K; Baba E
    Sci Rep; 2021 Feb; 11(1):2741. PubMed ID: 33531609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma.
    Lu T; Chen Y; Gong X; Guo Q; Lin C; Luo Q; Tu Z; Pan J; Li J
    Cancer Med; 2021 Nov; 10(21):7847-7862. PubMed ID: 34590792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis.
    Tang L; Liu T; Chen J; Dang J; Li G
    Immunotherapy; 2021 Apr; 13(6):541-555. PubMed ID: 33629592
    [No Abstract]   [Full Text] [Related]  

  • 16. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
    Chandrasekara S; Davis S; Thomson P; Haydon A
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e442-e447. PubMed ID: 29345108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 18. No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma.
    Voortman J
    Lancet Oncol; 2024 May; 25(5):533-534. PubMed ID: 38697152
    [No Abstract]   [Full Text] [Related]  

  • 19. Neutrophil-to-lymphocyte ratio as a prognostic indicator for overall and cancer-specific survival in squamous cell carcinoma of the head and neck.
    Ferrandino RM; Roof S; Garneau J; Haidar Y; Bates SE; Park YA; Bauml JM; Genden EM; Miles B; Sigel K
    Head Neck; 2020 Oct; 42(10):2830-2840. PubMed ID: 32592262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment.
    Lorini L; Merlano M; Licitra L; Ravanelli M; Bossi P
    Oral Oncol; 2021 May; 116():105138. PubMed ID: 33390267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.